Thiopurine S-methyltransferase (TPMT) deficiency increases the risk of serious adverse events in persons receiving thiopurines. The objective was to synthesize reported sensitivity and specificity of TPMT phenotyping and genotyping using a latent class hierarchical summary receiver operating characteristic meta-analysis. In 27 studies, pooled sensitivity and specificity of phenotyping for deficient individuals was 75.9% (95% credible interval (CrI), 58.3-87.0%) and 98.9% (96.3-100%), respectively. For genotype tests evaluating TPMT*2 and TPMT*3, sensitivity and specificity was 90.4% (79.1-99.4%) and 100.0% (99.9-100%), respectively. For individuals with deficient or intermediate activity, phenotype sensitivity and specificity was 91.3% (86.4-95.5%) and 92.6% (86.5-96.6%), respectively. For genotype tests evaluating TPMT*2 and TPMT*3, sensitivity and specificity was 88.9% (81.6-97.5%) and 99.2% (98.4-99.9%), respectively. Genotyping has higher sensitivity as long as TPMT*2 and TPMT*3 are tested. Both approaches display high specificity. Latent class meta-analysis is a useful method for synthesizing diagnostic test performance data for clinical practice guidelines.
INTRODUCTION
Thiopurine S-methyltransferase (TPMT) is an enzyme that metabolizes thiopurines, a class of drugs used in childhood leukemias, inflammatory bowel disease, dermatological conditions and in transplant recipients. Unless thiopurine drugs are avoided or doses reduced in patients with absent or deficient TPMT activity, they are at greater risk for life-threatening bone marrow toxicity and liver toxicity, which may lead to myelosuppression, anemia, bleeding, leukopenia, infection or death. 1 There are two approaches to testing for TPMT deficiency. Phenotype tests that measure levels of TPMT enzyme activity in vitro are common. [2] [3] [4] [5] [6] Alternatively, genotype tests are available that detect the presence of variants in the genes responsible for expressing the TPMT enzyme. [7] [8] [9] Both tests have associated challenges and it remains uncertain whether an enzyme activity (phenotype) or genotype diagnostic test is the most appropriate strategy.
Phenotype test results can be confounded by concomitant medications or blood transfusions. In addition, the choice of cutpoints is crucial. A low enzyme activity cut-point (for example, below 5 U per ml packed red blood cells) is used for identifying patients with deficient TPMT activity in whom thiopurines should be avoided, and an intermediate cut-point (for example, below 15 U per ml packed red blood cells) is used for identifying patients with reduced activity for whom a reduced dose would be safer. The choice of cut-point is influenced by the patient population and the clinical indication for testing, as it may be acceptable to tolerate a higher risk of an adverse drug event (ADE) for a greater chance of successful treatment for certain patient populations. 10 Genotype tests are limited by the number of genes that can be tested simultaneously (either due to methodological or cost constraints). Although there are 24 genes known to be implicated in TPMT, three variants (*3A, *14A and *22) account for 90% of the deficiencies occurring in the population. 11 Patients with these three variants have no detectable enzyme activity, whereas patients with other variants have~50% of functional enzyme activity. 11 The most common TPMT genomic tests include only TPMT*2 and TPMT*3, and as a result leave patients with rare mutations at risk. 11 The prevalence of mutations is known to vary by ethnic background, 5, [12] [13] [14] thus certain segments of the population may be more at risk.
Meta-analysis of diagnostic test accuracy
A diagnostic test's accuracy can be summarized by the test's sensitivity and specificity. If the test has a variable cut-point for defining a result as positive or negative, the sensitivity and specificity will vary together as the cut-point is changed. Receiver operating characteristic (ROC) analysis summarizes the inherent trade-offs between sensitivity and specificity as the decision threshold is made more or less stringent, and is an established methodology for the assessment of diagnostic test performance.
Determining the performance characteristics of TPMT phenotype and genotype tests would be aided by a meta-analysis of published findings. However, three difficulties exist. First, the meta-analysis of test performance is more complicated than metaanalysis of treatment effects from randomized controlled trials. [15] [16] [17] [18] Sensitivity and specificity are correlated and sophisticated analysis that allows these parameters to be pooled simultaneously is therefore required. [19] [20] [21] [22] Secondly, cut-points for distinguishing between normal and deficient TPMT enzyme activity vary between studies and patient populations resulting in heterogeneity in the data. Heterogeneity amongst sensitivity and specificity pairs makes it unreasonable to simply pool the results into a summary sensitivity and specificity pair. Ignoring the variable nature of the cut-point could lead clinicians to falsely conclude that two tests are different when they actually have the same discriminatory ability. Statistical models exist that attempt to account for varying cut-points between studies, but they have been challenging to use as they rely on computationally intense Bayesian models. 19, 21, 22 Third, neither the phenotype test nor the genotype test is a gold standard [23] [24] [25] that can independently accurately classify a case as positive or negative. Without a gold standard, phenotype and genotype tests can only be compared with each other, in other words, utilizing an imperfect reference standard. Therefore, a meta-analysis should either assume a missing gold standard or that the test selected as the reference standard (whether it is the phenotype or genotype test), is an imperfect reference standard.
Two methods exist that address these challenges: the bivariate method 26 and the hierarchical summary ROC curve method (HSROC). 21 When no meta-regression is performed it has been shown that both methods provide mathematically equivalent results. 27, 28 The difference is that the bivariate method provides summary sensitivity and specificity pairs whereas the HSROC method is parameterized in terms of accuracy and threshold, and generates a HSROC curve that best fits a group of sensitivity and specificity pairs. Therefore, diagnostic test accuracy (DTA) metaanalysis must address the issues of heterogeneity as well as correlation of parameters. A DTA meta-analysis for phenotype and genotype testing of TPMT must also address the issue of imperfect reference standards. The aim of this study was to meta-analyze the sensitivity and specificity of phenotype and genotype TPMT testing reported in the literature using a method that accounts for these issues.
MATERIALS AND METHODS
Data sources and searches A comprehensive systematic review of all published studies of TPMT test performance was initially conducted. 29 Study selection Additional details of literature search and retrieval, abstract review, data extraction and quality appraisal are reported elsewhere following PRISMA guidelines. 29 Eligible studies were those that: (1) evaluated either a TPMT genotype or TPMT phenotype technology in comparison to a reference standard; (2) presented results on the sensitivity and specificity or positive/negative predictive values together with prevalence, or allowed these measures to be calculated from data in the text, in supplemental files, or from data obtained from study authors; (3) were conducted in any age group; (4) were conducted in any disease group; and (5) were published in any language, so long as translation was possible. Studies not conducted in humans, including animal, tissue and in vitro studies were excluded.
Data extraction and quality assessment Data from each included study were extracted into a MS Access database. Data extraction included study design characteristics, study results, diagnostic test performance and data required to populate 2 × 2 contingency tables for the calculation of sensitivity and specificity. Articles typically categorized test results into three categories: deficient, intermediate or normal/high for phenotype testing and homozygous, heterozygous, or wild-type for genotype tests. An example of the distribution of patients within a population is shown in Supplementary Figure 1 , together with approximate cut-points for the phenotype test. However, receiver ROC analysis can only address binomial tests, therefore 2x2 contingency tables were estimated for analysis.
The Quality Assessment tool for Diagnostic Accuracy Studies (QUADAS) version 2 was used to evaluate the quality of included studies. 30 The QUADAS-2 contains four domains pertaining to risk of bias and applicability related to (i) patient selection, (ii) the index test, (iii) the reference standard, and (iv) flow and timing of the study. A fifth domain was created to assess the risk of bias pertaining specifically to genetic tests.
Data synthesis and analysis
The phenotype tests displayed a variety of cut-points throughout the various studies. A latent class meta-analysis method that allowed for heterogeneity in cut-point definition in phenotype testing while also allowing for an imperfect reference standard was selected. 24 Two different testing approaches were considered: (1) identifying patients with deficient or absent TPMT enzyme activity (patients that are homozygous for TPMT mutations) versus the rest of the population and (2) identifying patients that have either low or intermediate TPMT enzyme activity (patients that are homozygous or heterozygous for TPMT mutations) versus the rest of the population. The first of these is the more clinically relevant test, as patients with deficiency or homozygous for mutations are at greater risk of a serious ADE and need to have their drug regimen changed.
Meta-analysis statistical method A random effects model that accounted for between-test variability was used. The statistical model simultaneously estimated the SROC curve for the phenotype test, and sensitivity and specificity values for the genotype test. The model assumed that the data were conditionally independent. In other words, the model assumed that genotype test results were unrelated to phenotype test results for each case. A conditionally dependent model is available, 22, 31 but it is not well-specified and it was found that using such a model would consistently fail to fit the data. 32 The meta-analysis model can account for different reference tests. Because the sensitivity and specificity of the genotype test varies with the polymorphisms tested, studies were stratified based on the polymorphisms included in the test. This resulted in two strata for the test of deficient TPMT enzyme activity/ homozygous TPMT mutation versus the rest of the population: (1) studies where the genotype test only considered TPMT*2 and *3, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] and (2) studies where the genotype test considered TPMT*2, TPMT*3 and additional polymorphisms. [43] [44] [45] There were three strata for the test of low or intermediate TPMT enzyme activity/homozygous or heterozygous TPMT mutation versus the rest of the population: (1) studies where the genotype test only considered TPMT*3, 46, 47 (2) studies where the genotype test considered TPMT*2 and TPMT*3, 6, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [48] [49] [50] [51] [52] [53] [54] [55] [56] and (3) studies where the genotype test considered TPMT*2, TPMT*3 and additional polymorphisms. [42] [43] [44] [45] 57, 58 The meta-analysis used a Bayesian model. Non-informative prior distributions that allowed the data to dominate the final estimate of the SROC curve and sensitivity and specificity values were used. Factors for meta-regression were not included because the number of studies was not large enough. Estimates of the mean and 95% credible intervals (CrI) of the pooled sensitivity and specificity for the phenotype test across all studies, and for the genotype test pooled by strata based on the number of polymorphisms tested, were derived. An SROC curve was estimated for phenotype TPMT testing. Analyses were carried out in WinBUGS version 1.4.3 and R version 3.0.2 using existing programs. 59 Results are presented in forest plots listing studies alphabetically with associated sensitivity and specificity values and plots of associated 95% confidence intervals (CI). The meta-analysis for (1) distinguishing between individuals with deficient activity versus others and (2) distinguishing between individuals with deficient or intermediate activity versus others are displayed in SROC curves overlaid onto the studies' sensitivity and specificity pairs. A pooled sensitivity and specificity estimate is provided on each SROC curve with an associated 95% CrIs.
RESULTS

Search results
Of 4071 potentially eligible studies identified through literature searches, 55 studies contained phenotype-genotype comparisons and were evaluated for inclusion in the meta-analysis. A PRISMA flow diagram is presented in Supplementary Figure 2 . Of these, 13 studies were of high quality and provided sufficient data for the analysis of deficient TPMT activity versus the remainder of the population and 27 high-quality studies provided sufficient data for the analysis of deficient or intermediate TPMT activity versus the remainder of the population.
The sample and laboratory test characteristics for each study are presented in Supplementary Table 1 . The most common test populations included healthy individuals, as well as patients with inflammatory bowel disease or acute lymphoblastic leukemia. The primary amplification method was PCR, and the majority of genotype tests used allele-specific PCR or restriction fragment length polymorphism. Most studies tested TPMT*2 and TPMT*3 polymorphisms. The majority of phenotype tests used radiochemical method or high-performance liquid chromatography testing and defined cut-points to classify patients as either deficient, low activity or normal/high activity. Figure 1 summarizes the data related to the 13 studies that assessed testing for deficient TPMT enzyme activity/homozygous TPMT mutations. The prevalence of deficient TPMT enzyme activity or homozygous TPMT mutations ranged from 0.002 to 0.142. Ranges for sensitivity and specificity of the genotype test reference standard were 50-100% and 88-100%, respectively. The forest plots show 11/13 studies having perfect sensitivity. However, eight of those studies had 95% CIs that covered nearly the full range of possible values due to the very low prevalence of deficient TPMT activity (1 or 2 cases with deficient TPMT activity per study). Eleven of 13 studies demonstrated perfect specificity with narrow 95% CIs. Figure 2 summarizes results from 27 studies identifying cases of deficient or intermediate TPMT enzyme activity (higher cutpoint). The prevalence of deficient or intermediate TPMT enzyme activity ranged from 0.023 to 0.557. Ranges for sensitivity and specificity of the genotype test reference standard were 60-100% and 60-100%, respectively. The forest plots show 12/27 studies having perfect sensitivity, however the 95% CIs of these estimates were narrower than seen in Figure 1 due to the higher prevalence of detecting low or intermediate TPMT activity. The specificities were high but only 2/13 studies had perfect specificity and the 95% CIs were narrow. The forest plots in Figure 2 show more heterogeneity than the plots in Figure 1 , further justifying the use of a random effects model to account for between-test variability.
Meta-analysis
On the basis of the latent class model, the pooled sensitivity and specificity of phenotype testing to detect individuals with TPMT deficiency versus others was 75.9% (95% CrI, 58.3-87.0%) and 98.9% (95% CrI, 96.3-100%), respectively. Figure 3 presents the summary ROC curve with the pooled estimates and the 95% credible region. The latent class meta-analysis model also provided pooled sensitivity and specificity of the genotype tests. For genotype tests evaluating TPMT*2 and TPMT*3, the pooled sensitivity and specificity was 90.4% (95% CrI, 79.1-99.4%) and 100.0% (95% CrI, 99.9-100%), respectively. For genotype tests evaluating TPMT*2, TPMT*3 and more polymorphisms, the pooled sensitivity and specificity was 80.7% (95% CrI, 41.7-99.4%) and 99.9% (95% CrI, 99.7-100%), respectively.
The pooled sensitivity and specificity of phenotype testing to detect individuals with deficient or intermediate TPMT activity versus others was 91.3% (95% CrI, 86.4-95.5%) and 92.6% (95% CrI, 86.5-96.6%), respectively. Figure 4 presents the SROC curve with the pooled estimates and the associated 95% credible region. For genotype tests evaluating TPMT*3 mutations only, the pooled sensitivity and specificity was 66.8% (95% CrI, 51.1-94.6%) and 99.9% (95% CrI, 99.5-100%), respectively. For genotype tests evaluating TPMT*2 and TPMT*3, the pooled sensitivity and specificity was 88.9% (95% CrI, 81.6-97.5%) and 99.2% (95% CrI, 98.4%-99.9%), respectively. For genotype tests evaluating TPMT*2, TPMT*3, and more polymorphisms, the pooled sensitivity and specificity was 93.5% (95% CrI, 84.9-99.3%) and 99.9% (95% CrI, 99.7-100%), respectively.
DISCUSSION
Of the 13 studies discriminating individuals with TPMT deficiency versus the remainder of the population, ten reported on genotype tests evaluating only TPMT*2 and TPMT*3, and three studies reported on detection of these and other polymorphisms. The individual study estimates of sensitivity displayed wide 95% CIs due to the small number of patients with deficient TPMT enzyme activity or a homozygous TPMT mutation. In 13 studies enrolling a total of 10 956 subjects, only 69 individuals had deficient TPMT enzyme activity or a homozygous TPMT mutation. However, as shown in Figure 1 , although the sensitivity estimates were uncertain, point estimates of specificity were close to 100% with narrow 95% CIs. Among the 27 studies discriminating individuals with TPMT deficiency or intermediate activity versus the remainder of the population, two studies reported on genotype tests evaluating only TPMT*3, 19 reported on genotype tests evaluating TPMT*2 and TPMT*3, and six studies reported on genotype tests evaluating TPMT*2, TPMT*3 and more polymorphisms.
Surprisingly, when distinguishing deficient TPMT activity from the remainder of the population, the genotype tests evaluating TPMT*2, TPMT*3, and more polymorphisms had a lower sensitivity than genotype tests evaluating TPMT*2 and TPMT*3 only. When distinguishing deficient or intermediate TPMT activity from the remainder of the population, as expected, the genotype test evaluating TPMT*2 and TPMT*3 had higher sensitivity than the test evaluating TMPT*3 only and lower sensitivity than the test evaluating TPMT*2, TPMT*3 and more. Because of the large 95% CrI associated with the sensitivity estimates however, none of differences achieved statistical significance. As a result, the metaanalysis was not able to demonstrate improved clinical validity when testing for more polymorphisms than TPMT*2 and TPMT*3 alone.
In the systematic review undertaken before this meta-analysis, the calculated sensitivity for genotyping to identify a homozygous mutation ranged from 0.0% to 100.0% and the calculated specificity ranged from 97.8% to 100.0%.The calculated sensitivity to detect a homozygous or heterozygous mutation ranged from 13.4% to 100.0% and the calculated specificity ranged from 90.9% to 100.0%. 29 A previous systematic review by Donnan et al. reported ranges for the sensitivity and specificity of the TPMT genotype test of 55-100% and 94-100%, respectively. The TPMT phenotype test sensitivity and specificity ranged from 92% to 100% and from 86% to 98%, respectively. 60 A meta-analysis by Booth et al. for discriminating between patients with low or intermediate TPMT enzyme activity (homozygous or heterozygous TPMT mutations) Due to the rarity of the homozygous mutation, Booth et al. did not meta-analyze tests discriminating between patients with deficient TPMT enzyme activity (homozygous TPMT mutation) and the rest of the population.
Although there are many more studies of testing patients with low or intermediate TPMT enzyme activity (homozygous or heterozygous TPMT mutation) versus the rest of the population, these studies do not address the most pressing clinical issue: identifying patients who are at greatest risk of ADEs from thiopurine drugs. Although the test to detect low or intermediate TPMT enzyme activity (homozygous or heterozygous TPMT mutation) is the most feasible due to the low prevalence of homozygous patients, it does not provide sufficient guidance regarding whether doses of thiopurines should be reduced or avoided altogether. Generation of the ROC curve with better estimates of sensitivity and specificity could only be obtained by testing a sample large enough to include more cases with the homozygous mutation, which is often infeasible. This underscores the challenge of determining accurate performance metrics and clinical decision-making cut-points for any rare genetic variants that are implicated in drug metabolism-a challenge that is expected to become more common as the field of pharmacogenomics expands.
A latent class meta-analysis statistical method was used to estimate the sensitivity and specificity of phenotype and genotype TPMT tests. The method used was sensitive to starting values, but it was found that results either converged to reasonable results or to boundary conditions that were highly unrealistic (for example, sensitivity = 0, specificity = 1). Another method was available with different model assumptions (the conditionally dependent model) but the software would not find a solution that fit the data (that is, could not converge).
It is clear that meta-analysis of diagnostic test accuracy should not consist of simply pooling or averaging sensitivity and specificity values. This study has shown that statistical methods are available that can address the heterogeneity of DTA studies, can address the correlation of sensitivity and specificity estimates, and can also address the issue of imperfect references standards should they exist. Although computationally intensive, these analyses were not technically challenging to implement. 59, 62 A strength of this study was that estimates of phenotype and genotype sensitivity and specificity were calculated simultaneously. The latent class meta-analysis method used addresses the correlation of sensitivity and specificity values as well as the imperfect nature of the available reference standards. A full SROC curve was estimated for phenotype TPMT testing as well. Another strength was that it was possible to conduct the meta-analysis in a useful sample of 27 high-quality studies.
A limitation was that the QUADAS-2 tool used to appraise the literature was not designed to classify studies as high or low quality, or to assign a numeric score. Rather, the tool allowed reviewers to summarize issues of bias and applicability. However, the QUADAS-2 is recommended by the Cochrane group as it enables a systematic evaluation of the risk of bias and lack of applicability of individual studies. It also allowed for inclusion of a customized genomics domain. 63 Another limitation was that the meta-analysis could not be stratified by ethnic group. The incidence of TPMT polymorphisms varies by ethnicity and this may result in different values for sensitivity and specificity for the genotype test. It may be inappropriate to apply results derived from pooling studies of heterogeneous populations to test selection for specific ethnic groups. Finally, the meta-analysis was forced to assume conditional independence between the phenotype and genotype tests. . Hierarchical summary ROC curve for the phenotype test discriminating deficient TPMT individuals versus others. The summary receiver operating characteristics curve was estimated from a latent class meta-analysis model assuming imperfect reference standards. Small dots represent the sensitivity and specificity of individual studies and the large dot represents the pooled sensitivity and specificity. The ellipse around the pooled sensitivity and specificity represented the 95% credible region for the pooled sensitivity and specificity. The summary receiver operating characteristics curve is estimated from a latent class meta-analysis model assuming imperfect reference standards. Small dots represent the sensitivity and specificity of individual studies and the large dot represents the pooled sensitivity and specificity. The ellipse around the pooled sensitivity and specificity represented the 95% credible region for the pooled sensitivity and specificity.
The conditionally dependent model is likely more appropriate because the genotype test detects polymorphisms of the gene that codes for the TPMT enzyme whose activity is measured by the phenotype test. Due to challenges with results that would not converge, the conditionally dependent model could not be used.
The pooled estimates of sensitivity suggest that genotyping has higher sensitivity than phenotyping as long as both TPMT*2 and TPMT*3 polymorphisms are tested. A high value for sensitivity is important in diagnostic applications to rule out the presence of deficiencies that may be associated with drug-related toxicity, thus allowing full therapeutic doses of thiopurines to be administered. However, the large 95% CrIs surrounding the sensitivity indicate that uncertainty is present. Both the genotype and phenotype tests demonstrated high specificity, useful for ruling in the presence of a deficiency.
This meta-analysis reflected the wide uncertainty evident in the TPMT diagnostic test literature. The question of diagnostic test accuracy is best addressed in large population studies of targeted ethnic groups, with sufficient numbers of patients with homozygous mutations to enable the determination of stable estimates. Despite the uncertainty surrounding the results, the pooled estimates for sensitivity and specificity of TPMT phenotype and genotype testing, together with 95% CrI information, are valuable for economic evaluations assessing the cost-effectiveness of one approach over another. Value of information methods may also be undertaken to determine the cost associated with collecting additional data to reduce the observed uncertainty. 64 The field of pharmacogenetic testing continues to grow, allowing more patients to benefit from a personalized approach to drug selection and dosing. 10 Whole-exome and whole-genome sequencing technologies are also evolving rapidly bringing the opportunity to simultaneously diagnose disease, identify risk of future diseases and identify drug metabolism deficiencies in a single test. 65 The positioning of pharmacogenetic testing for TPMT and other enzymatic deficiencies in the larger context of nextgeneration sequencing is an area for future research.
In conclusion, the pooled estimates of sensitivity suggest that genotype testing has higher sensitivity than phenotype testing as long as both TPMT*2 and TPMT*3 polymorphisms are tested. However, due to the large 95% CrIs around sensitivity estimates the results remain uncertain. Both tests have been shown to have high specificity. The HSROC methods applied in this study are recommended for DTA meta-analyses and are superior to simple pooling.
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